Shilpa Medicare Ltd. (BSE: 530549) is a Raichur, Karnataka-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹16,875 Cr, it ranks #391 by market cap among the 6,189 Indian listed companies on FinBizNet, and #18 of 86 in Medicinal Chemicals and Botanical Products. At ₹862.80 (as of 26 Oct 2026), the share price is 21.2% below its 52-week high of ₹1,095.00 and 223.1% above its 52-week low of ₹267.00. The share price is up 142.0% over one year and up 42.6% over three months.
| Current Price | ₹862.80 |
|---|---|
| Market Cap | ₹16,875 Cr |
| BSE Code | 530549 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 69.4 |
| Return on Equity | 9.82% |
| Return on Assets | 4.68% |
| 52-Week Range | ₹267.00 – ₹1,095.00 |
| 1-Year Price Change | +142.0% |
| 3-Month Price Change | +42.6% |
| Beta (1Y) | 0.31 |
| Dividend Yield | 0.07% |
| Headquarters | Raichur, Karnataka |
| Website | www.vbshilpa.com |
| Revenue | ₹466 Cr |
|---|---|
| Net Profit | ₹95 Cr |
| Net Margin | 20.4% |
| EPS (Basic) | ₹5.16 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sora
1. Pharmaceutical Product and Wind Power Generation-This segment manufactures and sells bulk drugs and intermediates. 2. Energy-0 3. Segment Adjustment-This segment is involved in the generation of wind power. 4. Bulk Drug & API-This segment is engaged in the manufacture and sale of bulk drugs and intermediates in India. It offers oncology products, active pharmaceutical ingredients, fine chemicals, herbal products, and specialty chemical products.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Shilpa Medicare Ltd. | ₹16,875 Cr | 69.4 | 9.82% | ₹466 Cr | +142.0% |
Listed by market capitalisation. Ratios are shown for context only.
Shilpa Medicare Ltd. is trading at ₹862.80, with a market capitalisation of ₹16,875 Cr.
Shilpa Medicare Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Shilpa Medicare Ltd. has a P/E of 69.4 and a return on equity of 9.82%.
Shilpa Medicare Ltd. is listed on the BSE under the scrip code 530549.
Shilpa Medicare Ltd.'s share price is up 142.0% over one year and up 42.6% over three months. Its 52-week range is ₹267.00 to ₹1,095.00.
In Q1 FY27, Shilpa Medicare Ltd. reported revenue of ₹466 Cr and net profit of ₹95 Cr, with basic EPS of ₹5.16 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.